Hexagon Nutrition IPO Review — Should You Apply?
Weak Demand Signals
Negative or zero grey market premium and low subscription indicate weak market sentiment.
Hexagon Nutrition IPO Review Summary
Hexagon Nutrition was one of the better-value mainboard offerings of the season — a specialised clinical-nutrition player at a modest 14.33x valuation — and investors responded with a 161.49x subscription and a healthy 6.7% listing gain.
The trade-off was the 100% OFS structure (no fresh capital) and only moderate return ratios. It suited value-minded investors comfortable with a niche, socially-relevant business; see how it compares on our IPO performance page. This is informational analysis based on available data, not investment advice.
Who Should Consider This IPO?
This IPO suited value investors drawn to a reasonably priced, specialised business with a genuine niche, as well as those seeking a modest listing gain backed by strong demand. If applying is new to you, see our how to apply for an IPO guide.
It was less suited to those wanting fresh-capital growth stories, given the 100% OFS, or investors seeking standout return ratios. Most apply via a discount demat account using UPI.
Detailed Investment Analysis
At the upper band of ₹45, Hexagon was valued at 14.33x earnings on an EPS of ₹2.93 — a modest, undemanding multiple that stood out as one of the more reasonably priced offerings of the season. That value pricing was likely a big reason for the strong response.
The financial profile is steady rather than spectacular. A 12.33% EBITDA margin and 17.06% ROCE are respectable for a nutrition-products business, and revenue of ₹267.59 Cr gives it decent scale. The specialised, regulated nature of medical nutrition also provides a modest moat.
On the risk side, the 100% OFS structure means no fresh capital for expansion, and a chunk of the business depends on government and institutional nutrition programmes, which can be tender-driven and lumpy. Raw-material costs and regulatory approvals in the food-and-nutrition space are the other watch-items.
The market liked the value on offer. The issue was subscribed 161.49x overall, led by NII at 161.49x, with QIB at 19.77x and retail a strong 26.85x — and the stock duly listed with a healthy gain, opening at ₹48 against the ₹45 issue price. Our IPO profit calculator can size the per-lot returns. Investors should consult a SEBI-registered financial advisor before making investment decisions.
Strengths
- An attractive, undemanding valuation at 14.33x earnings — one of the cheaper mainboard offerings of the season, leaving room for upside.
- A specialised niche in clinical nutrition and food fortification, which brings regulatory barriers and a modest social-impact moat.
- Steady profitability, with a 12.33% EBITDA margin and 17.06% ROCE that are solid for the nutrition space.
- Strong, broad-based demand, with the issue subscribed 161.49x overall across NII, QIB and retail.
- A healthy listing, with shares opening at ₹48 versus the ₹45 issue price — a 6.7% gain that rewarded allottees.
Risks & Concerns
- A 100% offer for sale means none of the ₹138.87 Cr reached the company — there's no fresh capital to fund expansion.
- Dependence on government and institutional nutrition programmes can make revenue tender-driven and lumpy from year to year.
- Only moderate return ratios, with RONW of 12.46% — decent but not the standout numbers seen in some peers.
- Raw-material cost swings and food-nutrition regulatory approvals add operational risk to a specialised business.
- With the issue 161x oversubscribed, retail allotment was unlikely for most small applicants.
Want Full IPO Data?
This review focuses on analysis. For complete IPO details — GMP history, subscription day-wise, financial tables, allocation breakdown, and registrar/lead manager info — visit the full data page.
View Hexagon Nutrition IPO Full Details →Frequently Asked Questions
What was Hexagon Nutrition IPO's price band and lot size?
Hexagon Nutrition was priced at ₹42 to ₹45 per share, with a lot of 333 shares. At the upper band the minimum retail investment came to about ₹14,985, and the face value was ₹1.
What does Hexagon Nutrition do?
It makes micronutrient premixes, food-fortification blends, and medical-nutrition products — serving both public-health nutrition programmes and a commercial clinical-nutrition market.
How did Hexagon Nutrition perform on listing?
Well — after a strong 161.49x subscription, the stock opened at ₹48 against its ₹45 issue price, a listing gain of about 6.7%.
Was Hexagon Nutrition IPO fairly valued?
Yes — at 14.33x earnings it was one of the more reasonably priced mainboard offerings of the season, which helped drive the strong demand.
Disclaimer: This review is informational analysis based on publicly available data. It is NOT investment advice. The verdict is a data-driven signal, not a recommendation to buy or sell. IPO GMP is unofficial and unregulated. Consult a SEBI-registered financial advisor before making investment decisions. Stock market investments are subject to market risks.